Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6
Authors
Keywords
-
Journal
Journal of Clinical Medicine
Volume 10, Issue 8, Pages 1583
Publisher
MDPI AG
Online
2021-04-09
DOI
10.3390/jcm10081583
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia
- (2021) Ivan O. Rosas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy
- (2020) Ning Tang et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
- (2020) Jason D. Goldman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- COVID-19 cytokine storm: the interplay between inflammation and coagulation
- (2020) Ricardo J Jose et al. Lancet Respiratory Medicine
- Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study
- (2020) Krzysztof Tomasiewicz et al. Expert Review of Anti-Infective Therapy
- Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
- (2020) Bingwen Liu et al. JOURNAL OF AUTOIMMUNITY
- Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
- (2020) NEW ENGLAND JOURNAL OF MEDICINE
- Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
- (2020) Divij Mathew et al. SCIENCE
- IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study
- (2020) José María Galván-Román et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- An inflammatory cytokine signature predicts COVID-19 severity and survival
- (2020) Diane Marie Del Valle et al. NATURE MEDICINE
- Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
- (2020) John H. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia
- (2020) Olivier Hermine et al. JAMA Internal Medicine
- Cytokine Storm
- (2020) David C. Fajgenbaum et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
- (2020) Carlos Salama et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
- (2019) Sabue Mulangu et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome
- (2018) Robert Q. Le et al. ONCOLOGIST
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
- (2017) Timothy P. Sheahan et al. Science Translational Medicine
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More